First-in-Human Clinical Study with RNA-Immunotherapy Combination of IVAC-W-bre1-uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients
Laufzeit: 01.01.2024 - 31.12.2024
imported
Kurzfassung
Triple Negative Breast Cancer (TNBC)
Patients at high risk after surgery and adjuvant chemotherapy.